InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
0.00%
)
US TECH 100
19,196.00
(
0.15%
)
Dow Jones
38,589.16
(
0.00%
)
Brent Oil
82.57
(
0.54%
)
Bitcoin
65,646.13
(
-1.49%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 153

Thursday, 05/10/2018 9:53:57 AM

Thursday, May 10, 2018 9:53:57 AM

Post# of 438
RARE now has 2 FDA-approved drugs: Mepsevii and Crysvita

Q-1/2018 reported cash of $571mn, providing a runway thru the end of 2018.

They sold their priority review voucher and this one-timer is the reason for Q-1 profitability.

RARE may need another equity offering if Crysvita launch goes poorly.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up